Globus Medical (GMED)
(Delayed Data from NYSE)
$72.05 USD
+2.37 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $72.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.05 USD
+2.37 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $72.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.
Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Globus Medical (GMED) Gains From NuVasive Buyout, Innovation
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
GMED or ABCM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. ABCM: Which Stock Is the Better Value Option?
Here's Why You Should Buy Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.
Globus Medical (GMED) Launches NuVasive's NSO in Global Market
by Zacks Equity Research
Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.
Globus Medical (GMED) Completes NuVasive Merger Agreement
by Zacks Equity Research
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.
Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.
Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings
by Zacks Equity Research
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Gains on Innovation, Strategic Deal
by Zacks Equity Research
Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.
ITGR or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.
Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe
by Zacks Equity Research
Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?